Thrombin activatable fibrinolysis inhibitor plasma levels and TAFI Thr325Ile genetic polymorphism in a cohort of Egyptian sickle cell disease patients and impact on disease severity

• Published in: Pediatric blood & cancer Vol. 71; no. 6; pp. e30959 - n/a
• Main Authors: Hamdy, Mona, Shaheen, Iman A., Khallaf, Mohamed, Selim, Yasmeen M. M.
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.06.2024
• Subjects: Adolescent; Adult; Anemia, Sickle Cell - blood; Anemia, Sickle Cell - genetics; Carboxypeptidase B2 - blood; Carboxypeptidase B2 - genetics; Case-Control Studies; Child; Child, Preschool; Cohort Studies; Egypt; Female; Fibrinolysis; Gene polymorphism; Genotype; Genotyping; Humans; Hypertension; Male; Plasma; Plasma levels; Plasmin; Polymorphism; Polymorphism, Single Nucleotide; Prognosis; Pulmonary hypertension; severity; Severity of Illness Index; Sickle cell disease; Single-nucleotide polymorphism; Statistical analysis; Thr325Ile SNP; Thrombin; thrombin activatable fibrinolysis inhibitor; Thrombosis; Vascular diseases; Young Adult; Egypt; Thr325Ile SNP; severity; thrombin activatable fibrinolysis inhibitor; sickle cell disease

Background Thrombin is a critical protease modulating thrombosis as well as inflammation, which are one of the main pathophysiological mechanisms in sickle vasculopathy, and its levels were reported to be high in sickle cell disease (SCD). The thrombin–thrombomodulin complex activates the TAFI inhib...